ERBB2 and breast carcinoma: Furthermore, activation of WNT3 was observed to stimulate the WNT/β-catenin pathway and an epithelial-mesenchymal transition (EMT)-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells [60].